fda compounding glp-1 🚨 Cracks Down on Compounded GLP-1s – What's Next for Weight Loss? 🚨 Big news in the weight loss world: The FDA is officially shutting down pharmacies producing medications Despite FDA ruling, compounded GLP-1s

Options for switching include moving from injectable to oral or sublingual semaglutide , transitioning between tirzepatide and semaglutide , or considering a dose conversion to a different GLP-1 agonist at a lower relative dose

What am I seeing in my practice related to thyroid

Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC focus seminar

Third, long-term adherence and safety of the combination therapy need to be further addressed

JAMA neurol

Researchers have found diseases including cardiovascular disease, non-alcoholic fatty liver disease, diabetic chronic kidney disease, osteoarthritis, autoimmune disease, alcohol use disorder and more could be positively impacted by GLP-1RA therapy